Cyclooxygenase and 5-lipoxygenase inhibitors protect against mononuclear phagocyte neurotoxicity

Neurobiology of Aging

Volumn 23, Issue 5, 2002, Pages 787-794

  Klegeris, Andis ^a   McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

5 Lipoxygenase; Alzheimer's disease; Cyclooxygenase; Leukotrienes; Microglia; Neurodegeneration; Neuroinflammation; Nitric oxide; NO NSAIDs; NSAIDs; Prostaglandins

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ALPHA PENTYL 3 (2 QUINOLYLMETHOXY)BENZYL ALCOHOL; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; FLURBIPROFEN; IBUPROFEN DERIVATIVE; INDOMETACIN DERIVATIVE; LEUKOTRIENE DERIVATIVE; LIPOXYGENASE INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROSTAGLANDIN DERIVATIVE; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR;

ARTICLE; CELL ACTIVATION; CELL CULTURE; CELL LINE; CELL SURVIVAL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROGLIA; MONONUCLEAR PHAGOCYTE; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; RESPIRATORY BURST; SUPERNATANT;

AGING; ALZHEIMER DISEASE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARACHIDONATE 5-LIPOXYGENASE; CYCLOOXYGENASE INHIBITORS; HUMANS; IBUPROFEN; INDOLES; LEUKOCYTES, MONONUCLEAR; LIPOXYGENASE INHIBITORS; MICROGLIA; NERVE DEGENERATION; NEUROBLASTOMA; NITRIC OXIDE; NITROBENZENES; PHAGOCYTES; SULFONAMIDES; TUMOR CELLS, CULTURED;

EID: 0036753450     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0197-4580(02)00021-0     Document Type: Article

References (51)

1. Arai K., Nishiyama N., Matsuki N., Ikegaya Y. Neuroprotective effects of lipoxygenase inhibitors against ischemic injury in rat hippocampal slice cultures. Brain Res. 904:2001;167-172.
2. Awni W.M., Braeckman R.A., Cavanaugh J.H., Locke C.S., Linnen P.J., Granneman G.R.et al. The pharmacokinetic and pharmacodynamic interactions between the 5-lipoxygenase inhibitor zileuton and the cyclooxygenase inhibitor naproxen in human volunteers. Clin. Pharmacokinet. 29(Suppl 2):1995;112-124.
3. Baskaya M.K., Hu Y., Donaldson D., Maley M., Rao A.M., Prasad M.R.et al. Protective effect of the 5-lipoxygenase inhibitor AA-861 on cerebral edema after transient ischemia. J. Neurosurg. 85:1996;112-116.
4. Bazan N.G., Rodriguez de Turco E.B., Allan G. Mediators of injury in neurotrauma: intracellular signal transduction and gene expression. J. Neurotrauma. 12:1995;791-814.
5. Bekemeier H., Hirschelmann R., Ramanampison M.L., Pantovic D. Simultaneous and sequential inhibition of the arachidonic acid cascade by inhibitors of phospholipase A2, cyclooxygenase and lipoxygenases in carrageenan edema and adjuvant arthritis in the rat [German]. Pharmazie. 41:1986;406-408.
6. Bell R.L., Harris R.R. The enzymology and pharmacology of 5-lipoxygenase and 5-lipoxygenase activating protein. Clin. Rev. Allerg. Immunol. 17:1999;91-109.
7. Berr C., Balansard B., Arnaud J., Roussel A.M., Alperovitch A. Cognitive decline is associated with systemic oxidative stress: the EVA study. Etude du Vieillissement Arteriel. J. Am. Geriatr. Soc. 48:2000;1285-1291.
8. 2· forming NADPH oxidase in microglia, monocytes, and neutrophils. A possible inflammatory mechanism of neuronal damage in Alzheimer's disease. J. Biol. Chem. 274:1999;15493-15499.
9. Boyle E.A., McGeer P.L. Cellular immune responses in multiple sclerosis plaques. Am. J. Pathol. 137:1990;575-584.
10. Bruce-Jones P.N.E., Crome P., Kalra L. Indomethacin and cognitive function in healthy elderly volunteers. Br. J. Clin. Pharmacol. 38:1994;45-51.
11. Buttgereit F., Burmester G.R., Simon L.S. Gastrointestinal toxic side effects of non-steroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors. Am. J. Med. 110(Suppl 3A):2001;13S-19S.
12. Crooks S.W., Stockley R.A. Leukotriene B4. Int. J. Biochem. Cell Biol. 30:1998;173-178.
13. Decker T., Lohmann-Matthes M.-L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J. Immunol. Meth. 15:1988;61-69.
14. Del Soldato P., Sorrentino R., Pinto A. NO-aspirins: a class of new anti-inflammatory and anti-thrombotic agents. Trends Pharmacol. Sci. 20:1999;319-323.
15. Dipatre P.L., Gelman B.B. Microglial cell activation in aging and Alzheimer disease: partial linkage with neurofibrillary tangle burden in the hippocampus. J. Neuropathol. Exp. Neurol. 56:1997;143-149.
16. Fiorucci S. NO-releasing NSAIDs are caspase inhibitors. Trends Immunol. 22:2001;232-235.
17. Hansen M.B., Nielsen S.E., Berg K. Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J. Immunol. Meth. 119:1989;203-210.
18. Hariri R.J., Ghajar J.B., Pomerantz K.B., Hajjar D.P., Giannuzzi R.F., Tomich E.et al. Human glial cell production of lipoxygenase-generated eicosanoids: a potential role in the pathophysiology of vascular changes following traumatic brain injury. J. Trauma Injury Infect Crit. Care. 29:1989;1203-1210.
19. Jama J.W., Launer L.J., Witteman J.C.M., Denbreeijen J.H., Breteler M.M.B., Grobbee D.E.et al. Dietary antioxidants and cognitive function in a population-based sample of older persons: the Rotterdam study. Am. J. Epidemiol. 144:1996;275-280.
20. Kawamata T., Akiyama H., Yamada T., McGeer P.L. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord. Am. J. Pathol. 140:1992;691-707.
21. Klegeris A., McGeer P.L. Inhibition of respiratory burst in macrophages by complement receptor blockade. Eur. J. Pharmacol. 260:1994;273-277.
22. Klegeris A., McGeer P.L. Rat brain microglia and peritoneal macrophages show similar responses to respiratory burst stimulants. J. Neuroimmunol. 53:1994;83-90.
23. Klegeris A., McGeer P.L. Interaction of various intracellular signaling mechanisms involved in mononuclear phagocyte toxicity toward neuronal cells. J. Leukoc. Biol. 67:2000;127-133.
24. Klegeris A., McGeer P.L. R-(-)-Deprenyl inhibits monocytic THP-1 cell neurotoxicity independently of monoamine oxidase inhibition. Exp. Neurol. 166:2000;458-464.
25. Klegeris A., Walker D.G., McGeer P.L. Toxicity of human THP-1 monocytic cells towards neuron-like cells is reduced by non-steroidal anti-inflammatory drugs (NSAIDs). Neuropharmacology. 38:1999;1017-1025.
26. Kusner E.J., Marks R.L., Aharony D., Krell R.D. Inhibition by REV 5901 of leukotriene release from guinea pig and human lung tissues in vitro. Biochem. Pharmacol. 38:1989;4183-4189.
27. Lichtenberger L.M. Where is the evidence that cyclooxygenase inhibition is the primary cause of non-steroidal anti-inflammatory drug (NSAID)-induced gastrointestinal injury? Topical injury revisited. Biochem. Pharmacol. 61:2001;631-637.
28. Mackenzie I.R.A., Munoz D.G. Non-steroidal anti-inflammatory drug use and Alzheimer-type pathology in aging. Neurology. 50:1998;986-990.
29. Manev H. 5-Lipoxygenase gene polymorphism and onset of Alzheimer's disease. Med. Hypotheses. 54:2000;75-76.
30. Manev H., Uz T., Sugaya K., Qu T. Putative role of neuronal 5-lipoxygenase in an aging brain. FASEB J. 14:2000;1464-1469.
31. McGeer P.L., Itagaki S., Boyes B.E., McGeer E.G. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 38:1988;1285-1291.
32. McGeer P.L., Schulzer M., McGeer E.G. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiological studies. Neurology. 47:1996;425-432.
33. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Meth. 65:1983;55-63.
34. Munsiff A.V., Chander P.N., Levine S., Stier C.T. Jr. The lipoxygenase inhibitor phenidone protects against proteinuria and stroke in stroke-prone spontaneously hypertensive rats. Am. J. Hypertens. 5:1992;56-63.
35. Neuroinflammation Working Group. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421.
36. Ohtsuki T., Matsumoto M., Hayashi Y., Yamamoto K., Kitagawa K., Ogawa S.et al. Reperfusion induces 5-lipoxygenase translocation and leukotriene C4 production in ischemic brain. Am. J. Physiol. 268:1995;H1249-H1257.
37. Perkins A.J., Hendrie H.C., Callahan C.M., Gao S.J., Unverzagt F.W., Xu Y.et al. Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 150:1999;37-44.
38. Peters-Golden M., Brock T.G. Intracellular compartmentalization of leukotriene synthesis: unexpected nuclear secrets. FEBS Lett. 487:2001;323-326.
39. Rogers J., Kirby L.C., Hempelman S.R., Berry D.L., McGeer P.L., Kaszniak A.W.et al. Clinical trial of indomethacin in Alzheimer's disease. Neurology. 43:1993;1609-1611.
40. Rozzini R., Ferrucci L., Losonczy K., Havlik R.J., Guralnik J.M. Protective effect of chronic NSAID use on cognitive decline in older persons. J. Am. Geriatr. Soc. 44:1996;1025-1029.
41. Saag K.G., Rubenstein L.M., Chrischilles E.A., Wallace R.B. Non-steroidal anti-inflammatory drugs and cognitive decline in the elderly. J. Rheumatol. 22:1995;2142-2147.
42. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 220:1983;568-575.
43. Sano M., Ernesto C., Thomas R.G., Klauber M.R., Schafer K., Grundman M.et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. New Engl. J. Med. 336:1997;1216-1222.
44. Scharf S., Mander A., Ugoni A., Vajda F., Christophidis N. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease. Neurology. 53:1999;197-201.
45. Sheffield L.G., Berman N.E.J. Microglial expression of MHC class II increases in normal aging of non-human primates. Neurobiol. Aging. 19:1998;47-55.
46. Shimohama S., Tanino H., Kawakami N., Okamura N., Kodama H., Yamaguchi T.et al. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem. Biophys. Res. Commun. 273:2000;5-9.
47. Sloane J.A., Hollander W., Moss M.B., Rosene D.L., Abraaham C.R. Increased microglial activation and protein nitration in white matter of the aging monkey. Neurobiol. Aging. 20:1999;395-405.
48. Sturmer T., Glynn R.J., Field T.S., Taylor J.O., Hennekens C.H. Aspirin use and cognitive function in the elderly. Am. J. Epidemiol. 143:1996;683-691.
49. Uz T., Pesold C., Longone P., Manev H. Aging-associated up-regulation of neuronal 5-lipoxygenase expression: putative role in neuronal vulnerability. FASEB J. 12:1998;439-449.
50. Van Muiswinkel FL, De Groot CJA, Rozemuller-Kwakkel JM, Eikelenboom P. Enhanced expression of microglial NADPH-oxidase (p22-phox) in Alzheimer's disease. In: Iqbal K, Swaab DF, Winblad B, Wisniewski HM, editors. Alzheimer's disease and related disorders: etiology, pathogenesis and therapeutics. Chichester, UK: Wiley, 1999. p. 451-5.
51. Walker DG, Lue L-F, Klegeris A, McGeer PL. Involvement of glial cell-derived reactive oxygen and nitrogen species in Alzheimer's disease. In: Rogers J, editor. Neuroinflammatory mechanisms in Alzheimer's disease: basic and clinical research. Boston: Birkhauser, 2001. p. 173-95.